Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain
PRINCIPLES: We aimed to evaluate the efficacy of, and treatment satisfaction with, insulin glargine administered with SoloSTAR® or ClikSTAR® pens in patients with type 2 diabetes mellitus managed by primary care physicians in Switzerland. METHODS: A total of 327 patients with inadequatel...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2015-02-01
|
| Series: | Swiss Medical Weekly |
| Subjects: | |
| Online Access: | https://www.smw.ch/index.php/smw/article/view/2013 |
| _version_ | 1798003735950000128 |
|---|---|
| author | Daniela Riebenfeld David Spirk Alexandra Mathis Lukas Villiger Philipp Gerber Urs Erwin Gasser Roger Lehmann |
| author_facet | Daniela Riebenfeld David Spirk Alexandra Mathis Lukas Villiger Philipp Gerber Urs Erwin Gasser Roger Lehmann |
| author_sort | Daniela Riebenfeld |
| collection | DOAJ |
| description |
PRINCIPLES: We aimed to evaluate the efficacy of, and treatment satisfaction with, insulin glargine administered with SoloSTAR® or ClikSTAR® pens in patients with type 2 diabetes mellitus managed by primary care physicians in Switzerland.
METHODS: A total of 327 patients with inadequately controlled type 2 diabetes were enrolled by 72 physicians in this prospective observational study, which aimed to evaluate the efficacy of a 6-month course of insulin glargine therapy measured as development of glycaemic control (glycosylated haemoglobin [HbA1c] and fasting plasma glucose [FPG]) and weight change. We also assessed preference for reusable or disposable pens, and treatment satisfaction.
RESULTS: After 6 months, the mean daily dose of insulin glargine was 27.7 ± 14.3 U, and dose titration was completed in 228 (72.4%) patients. Mean HbA1c decreased from 8.9% ± 1.6% (n = 327) to 7.3% ± 1.0% (n = 315) (p <0.0001), and 138 (43.8%) patients achieved an HbA1c ≤7.0%. Mean FPG decreased from 10.9 ± 4.5 to 7.3 ± 1.8 mmol/l (p <0.0001). Mean body weight did not change (85.4 ± 17.2 kg vs 85.0 ± 16.5 kg; p = 0.11). Patients’ preference was in favour of the disposable SoloStar® pen (80%), as compared with the reusable ClickStar® pen (20%). Overall, 92.6% of physicians and 96.3% of patients were satisfied or very satisfied with the insulin glargine therapy.
CONCLUSIONS: In patients with type 2 diabetes insulin glargine administered by SoloSTAR® or ClikSTAR® pens, education on insulin injection and on self-management of diabetes was associated with clinically meaningful improvements in HbA1c and FPG without a mean collective weight gain. The vast majority of both patients and primary care physicians were satisfied with the treatment intensification.
|
| first_indexed | 2024-04-11T12:12:30Z |
| format | Article |
| id | doaj.art-1b47094892fe4037ac08758acbe5514d |
| institution | Directory Open Access Journal |
| issn | 1424-3997 |
| language | English |
| last_indexed | 2024-04-11T12:12:30Z |
| publishDate | 2015-02-01 |
| publisher | SMW supporting association (Trägerverein Swiss Medical Weekly SMW) |
| record_format | Article |
| series | Swiss Medical Weekly |
| spelling | doaj.art-1b47094892fe4037ac08758acbe5514d2022-12-22T04:24:32ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972015-02-01145091010.4414/smw.2015.14114Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gainDaniela RiebenfeldDavid SpirkAlexandra MathisLukas VilligerPhilipp GerberUrs Erwin GasserRoger Lehmann PRINCIPLES: We aimed to evaluate the efficacy of, and treatment satisfaction with, insulin glargine administered with SoloSTAR® or ClikSTAR® pens in patients with type 2 diabetes mellitus managed by primary care physicians in Switzerland. METHODS: A total of 327 patients with inadequately controlled type 2 diabetes were enrolled by 72 physicians in this prospective observational study, which aimed to evaluate the efficacy of a 6-month course of insulin glargine therapy measured as development of glycaemic control (glycosylated haemoglobin [HbA1c] and fasting plasma glucose [FPG]) and weight change. We also assessed preference for reusable or disposable pens, and treatment satisfaction. RESULTS: After 6 months, the mean daily dose of insulin glargine was 27.7 ± 14.3 U, and dose titration was completed in 228 (72.4%) patients. Mean HbA1c decreased from 8.9% ± 1.6% (n = 327) to 7.3% ± 1.0% (n = 315) (p <0.0001), and 138 (43.8%) patients achieved an HbA1c ≤7.0%. Mean FPG decreased from 10.9 ± 4.5 to 7.3 ± 1.8 mmol/l (p <0.0001). Mean body weight did not change (85.4 ± 17.2 kg vs 85.0 ± 16.5 kg; p = 0.11). Patients’ preference was in favour of the disposable SoloStar® pen (80%), as compared with the reusable ClickStar® pen (20%). Overall, 92.6% of physicians and 96.3% of patients were satisfied or very satisfied with the insulin glargine therapy. CONCLUSIONS: In patients with type 2 diabetes insulin glargine administered by SoloSTAR® or ClikSTAR® pens, education on insulin injection and on self-management of diabetes was associated with clinically meaningful improvements in HbA1c and FPG without a mean collective weight gain. The vast majority of both patients and primary care physicians were satisfied with the treatment intensification. https://www.smw.ch/index.php/smw/article/view/2013primary carePatient empowermentType-2 diabetes mellitusinsulin glargineweightClikSTAR® |
| spellingShingle | Daniela Riebenfeld David Spirk Alexandra Mathis Lukas Villiger Philipp Gerber Urs Erwin Gasser Roger Lehmann Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain Swiss Medical Weekly primary care Patient empowerment Type-2 diabetes mellitus insulin glargine weight ClikSTAR® |
| title | Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain |
| title_full | Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain |
| title_fullStr | Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain |
| title_full_unstemmed | Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain |
| title_short | Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain |
| title_sort | treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain |
| topic | primary care Patient empowerment Type-2 diabetes mellitus insulin glargine weight ClikSTAR® |
| url | https://www.smw.ch/index.php/smw/article/view/2013 |
| work_keys_str_mv | AT danielariebenfeld treatmentintensificationwithinsulinglargineinpatientswithinadequatelycontrolledtype2diabetesimprovesglycaemiccontrolwithahightreatmentsatisfactionandnoweightgain AT davidspirk treatmentintensificationwithinsulinglargineinpatientswithinadequatelycontrolledtype2diabetesimprovesglycaemiccontrolwithahightreatmentsatisfactionandnoweightgain AT alexandramathis treatmentintensificationwithinsulinglargineinpatientswithinadequatelycontrolledtype2diabetesimprovesglycaemiccontrolwithahightreatmentsatisfactionandnoweightgain AT lukasvilliger treatmentintensificationwithinsulinglargineinpatientswithinadequatelycontrolledtype2diabetesimprovesglycaemiccontrolwithahightreatmentsatisfactionandnoweightgain AT philippgerber treatmentintensificationwithinsulinglargineinpatientswithinadequatelycontrolledtype2diabetesimprovesglycaemiccontrolwithahightreatmentsatisfactionandnoweightgain AT urserwingasser treatmentintensificationwithinsulinglargineinpatientswithinadequatelycontrolledtype2diabetesimprovesglycaemiccontrolwithahightreatmentsatisfactionandnoweightgain AT rogerlehmann treatmentintensificationwithinsulinglargineinpatientswithinadequatelycontrolledtype2diabetesimprovesglycaemiccontrolwithahightreatmentsatisfactionandnoweightgain |